Aptar Pharma is touting the use of its “Classic” modular spray pump in the recently launched Sprix ketorolac tromethamine nasal spray from Regency Therapeutics.
Regency is a new division of Luitpold Pharmaceuticals, which acquired Sprix developer Roxro in December 2010. Aptar had worked with Roxro for 7 years on development of the product, and Eric Hohenschuh, Sr. Manager, Marketing for Regency Therapeutics credits the company’s participation as one of Luitpold’s reasons for buying Roxro: “Aptar Pharma’s reputation for performance and quality was an important consideration in our acquisition of Sprix; we look forward to working with Aptar Pharma for many years to come.”
Read the Aptar press release.
